Neumora Therapeutics, Inc. (NMRA) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Neumora Therapeutics, Inc. (NMRA) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Neumora Therapeutics, Inc. (Stock Symbol: NMRA)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $262 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Neumora Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Neumora Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Neumora Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Neumora Therapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Neumora Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Neumora Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Neumora Therapeutics, Inc.: With a P/E ratio of -3.90, the market sees the stock as potentially undervalued.
P/E Ratio-3.90x
P/B Ratio1.43x
Market Cap$262M
EPS$-1.57
Book Value/Share$1.13
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Neumora Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Neumora Therapeutics, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Neumora Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Neumora Therapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Neumora Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Neumora Therapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Neumora Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Neumora Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Neumora Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Neumora Therapeutics, Inc.:
Income Statement ($ Millions)
R&D Expense$197M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding162M
Growth Metrics (YoY)
EPS Growth-21.9%
Neumora Therapeutics, Inc. (NMRA) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Neumora Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Neumora Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Neumora Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Neumora Therapeutics, Inc. (NMRA) stock price and investment outlook.
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire NEW YORK, Feb. 20, 2025 ...
Neumora Therapeutics Inc (NASDAQ:NMRA) is advancing an industry-leading pipeline targeting novel mechanisms of action for prevalent brain diseases. The company is on track to deliver topline data ...
If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame, you have until April 7, 2025 to request that the Court appoint you as lead plaintiff.
Bearish flow noted in Neumora Therapeutics (NMRA) Inc with 8,496 puts trading, or 8x expected. Most active are Jan-25 5 puts and Jan-25 15 calls, with total volume in those strikes near 8,300 ...
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA January 02, 2025 06:40 PM Eastern Standard Time ...
SAN DIEGO-- (BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or ...
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
So unless Neumora Therapeutics Inc sees its shares decline 53.3% and the contract is exercised (resulting in a cost basis of $3.30 per share before broker commissions, subtracting the $1.70 from ...
Neumora Therapeutics, Inc. (NASDAQ:NMRA) ranks as the 7th best small-cap stock ready to explode. Analysts’ 12-month median price target is pointing towards a 112.18% upside from current levels.
Neumora Therapeutics, backed by Amgen and Japan's SoftBank , is seeking a valuation of up to $2.74 billion in its U.S. initial public offering, as the biopharmaceutical company looks to ride a ...
Neumora Therapeutics Inc., a neuroscience startup aiming to launch precision medicines for brain diseases, said Oct. 7 it has raised more than $500 million, including a $100 million equity investment ...
Neumora Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Neumora Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Neumora Therapeutics, Inc. Stock Forecast
How accurate are Neumora Therapeutics, Inc. stock predictions?
Our AI model demonstrates 53% historical accuracy for NMRA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Neumora Therapeutics, Inc. stock price forecasts?
Is Neumora Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Neumora Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Neumora Therapeutics, Inc. forecasts updated?
Neumora Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Neumora Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Neumora Therapeutics, Inc. stock.
